This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2009 Apr 7;72(14):1202-3.

doi: 10.1212/01.wnl.0000345658.54511.31.

Dyskinesia in Parkinson disease: back for the future?

Francois J G Vingerhoets

PMID: 19349599
DOI: 10.1212/01.wnl.0000345658.54511.31

Editorial

Dyskinesia in Parkinson disease: back for the future?

Francois J G Vingerhoets. Neurology. 2009.

. 2009 Apr 7;72(14):1202-3.

doi: 10.1212/01.wnl.0000345658.54511.31.

Author

Francois J G Vingerhoets

PMID: 19349599
DOI: 10.1212/01.wnl.0000345658.54511.31

No abstract available

PubMed Disclaimer

Comment on

PET demonstrates reduced dopamine transporter expression in PD with dyskinesias.
Troiano AR, de la Fuente-Fernandez R, Sossi V, Schulzer M, Mak E, Ruth TJ, Stoessl AJ. Troiano AR, et al. Neurology. 2009 Apr 7;72(14):1211-6. doi: 10.1212/01.wnl.0000338631.73211.56. Epub 2008 Nov 19. Neurology. 2009. PMID: 19020294

Similar articles

Peak-dose dyskinesia; an acceptable price for mobility in late-stage Parkinson's disease?
Wenzelburger R. Wenzelburger R. Clin Neurophysiol. 2005 Sep;116(9):1997-8. doi: 10.1016/j.clinph.2005.06.009. Clin Neurophysiol. 2005. PMID: 16055380 No abstract available.
Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
Deleu D, Hanssens Y. Deleu D, et al. Neurology. 2006 May 23;66(10):1611-2; author reply 1611-2. Neurology. 2006. PMID: 16721952 No abstract available.
Continuous dopaminergic therapy in Parkinson disease: time to stride back?
Stoessl AJ. Stoessl AJ. Ann Neurol. 2010 Jul;68(1):3-5. doi: 10.1002/ana.22079. Ann Neurol. 2010. PMID: 20583222 No abstract available.
Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease.
Cheshire PA, Williams DR. Cheshire PA, et al. J Clin Neurosci. 2012 Mar;19(3):343-8. doi: 10.1016/j.jocn.2011.09.008. Epub 2012 Jan 16. J Clin Neurosci. 2012. PMID: 22249009 Review.
Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders.
Voon V, Fernagut PO, Wickens J, Baunez C, Rodriguez M, Pavon N, Juncos JL, Obeso JA, Bezard E. Voon V, et al. Lancet Neurol. 2009 Dec;8(12):1140-9. doi: 10.1016/S1474-4422(09)70287-X. Lancet Neurol. 2009. PMID: 19909912 Review.

See all similar articles

Cited by

Synthesis and in vitro pharmacological evaluation of indolyl carboxylic amide analogues as D₃ dopamine receptor selective ligands.
Tu Z, Li S, Li A, Taylor M, Ho D, Malik M, Luedtke RR, Mach RH. Tu Z, et al. Medchemcomm. 2013 Sep;4(9):1283-1289. doi: 10.1039/C3MD00098B. Medchemcomm. 2013. PMID: 24156012 Free PMC article.
Synthesis and pharmacological evaluation of fluorine-containing D₃ dopamine receptor ligands.
Tu Z, Li S, Cui J, Xu J, Taylor M, Ho D, Luedtke RR, Mach RH. Tu Z, et al. J Med Chem. 2011 Mar 24;54(6):1555-64. doi: 10.1021/jm101323b. Epub 2011 Feb 24. J Med Chem. 2011. PMID: 21348515 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information